Status: Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Verismo TherapeuticsUpdated: Apr 14, 2026Locations: 5
Eligibility criteria
Adult 18 years of age and older. [+7]
Previously treated with any investigational agent within 30 days prior to screen... [+5]